Edition:
United States

Bio-Techne Corp (TECH.OQ)

TECH.OQ on NASDAQ Stock Exchange Global Select Market

151.18USD
14 Dec 2018
Change (% chg)

$-4.49 (-2.88%)
Prev Close
$155.67
Open
$154.56
Day's High
$155.82
Day's Low
$151.01
Volume
55,828
Avg. Vol
98,238
52-wk High
$205.99
52-wk Low
$127.16

Latest Key Developments (Source: Significant Developments)

Bio-Techne Q2 GAAP Earnings Per Share $1.29
Tuesday, 6 Feb 2018 07:00am EST 

Bio-Techne Corp ::BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2018 RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $1.02.Q2 GAAP EARNINGS PER SHARE $1.29.Q2 SALES $154.2 MILLION.QTRLY GAAP EPS SAW A ONE-TIME BENEFIT OF $0.94 FROM TAX REFORM.  Full Article

Bio-Techne Acquires Atlanta Biologicals Inc
Tuesday, 2 Jan 2018 05:01pm EST 

Jan 2 (Reuters) - Bio-Techne Corp ::BIO-TECHNE ACQUIRES ATLANTA BIOLOGICALS INC.BIO-TECHNE CORP - ‍TRANSACTION IS FINANCED THROUGH AVAILABLE CASH ON HAND​.BIO-TECHNE - DEAL EXPECTED TO BE SLIGHTLY ACCRETIVE TO ADJUSTED EARNINGS PER SHARE FOR FISCAL YEAR 2018.  Full Article

Bio-Techne releases Q1 adjusted earnings per share $0.90
Tuesday, 31 Oct 2017 07:35am EDT 

Oct 31 (Reuters) - Bio-Techne Corp :Bio-Techne releases first quarter fiscal 2018 results.Q1 adjusted earnings per share $0.90.Q1 GAAP earnings per share $0.42.Q1 sales $144.6 million versus I/B/E/S view $142.9 million.Q1 earnings per share view $0.88 -- Thomson Reuters I/B/E/S.  Full Article

Bio-Techne releases serological assay to detect Zika virus infections
Wednesday, 6 Sep 2017 05:40pm EDT 

Sept 6 (Reuters) - Bio-techne Corp :Bio-Techne releases a highly sensitive and specific serological assay to detect Zika virus infections.‍R&D systems - release of new rapid, solid phase, ELISA designed to measure anti-zika virus immunoglobulin g (IgG) antibodies in human serum​.Research and Development Systems-ELISA kit can be used to detect prior infections, determine whether Zika virus may be linked to subsequent neurological disorders/fetal abnormalities​.Research and Development Systems- in-house testing shows kit is "highly sensitive" to anti-Zika virus IgG, displays minimal cross-reactivity with dengue virus IgG antibodies​.  Full Article

Bio-Techne acquires Trevigen Inc
Tuesday, 5 Sep 2017 06:07pm EDT 

Sept 6 (Reuters) - Bio-techne Corp :Bio-Techne acquires Trevigen Inc.Bio-Techne Corp says transaction is financed through available cash on hand.Bio-Techne Corp - ‍Acquisition is expected to be accretive to Bio-Techne's adjusted earnings per share for its fiscal year 2018​​.Bio-Techne Corp - ‍Has acquired all of stock of Trevigen Inc for cash​.  Full Article

Bio-Techne Q4 adjusted earnings per share $1.09
Tuesday, 8 Aug 2017 07:30am EDT 

Aug 8 (Reuters) - Bio-techne Corp :Bio-Techne releases fourth quarter fiscal 2017 results.Q4 adjusted earnings per share $1.09.Q4 gaap earnings per share $0.77.Q4 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.Q4 sales $156.6 million versus i/b/e/s view $150.1 million.  Full Article

Bio-Techne reports Q3 EPS $0.57
Tuesday, 2 May 2017 07:30am EDT 

May 2 (Reuters) - Bio-techne Corp :Bio-Techne releases third quarter fiscal 2017 results.Q3 adjusted earnings per share $0.97.Q3 GAAP earnings per share $0.57.Q3 revenue $144 million versus I/B/E/S view $142.7 million.Q3 earnings per share view $0.93 -- Thomson Reuters I/B/E/S.  Full Article

Bio-Techne Corp & Bio-Techne has entered into an exclusive license agreement
Tuesday, 7 Mar 2017 08:30am EST 

Bio-techne Corp : Bio-Techne Corp - Bio-Techne has entered into an exclusive license agreement with multiclonal therapeutics .Bio-Techne Corp - agreement to commercialize reagents and media systems in research reagent field.  Full Article

Bio-Techne Q2 adjusted earnings per share $0.81
Tuesday, 7 Feb 2017 07:30am EST 

Bio-techne Corp : Net sales for Q2 increased 9% to $131.8 million . Bio-Techne releases second quarter fiscal 2017 results . Q2 adjusted earnings per share $0.81 . Q2 gaap earnings per share $0.17 . Q2 revenue $131.8 million versus I/B/E/S view $134.5 million .Q2 earnings per share view $0.85 -- Thomson Reuters I/B/E/S.  Full Article